Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
INSM Stock Chart & Stats
$189.60
-$1.02(-1.54%)
At close: 4:00 PM EST
$189.60
-$1.02(-1.54%)
Day’s Range― - ―
52-Week Range$60.40 - $194.70
Previous CloseN/A
Volume462.72K
Average Volume (3M)2.04M
Market Cap
$40.44B
Enterprise ValueN/A
Total Cash (Recent Filing)$1.68B
Total Debt (Recent Filing)$36.56M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Feb 19, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding211,374,790
10 Day Avg. Volume1,783,268
30 Day Avg. Volume2,043,870
Financial Highlights & Ratios
PEG Ratio-2.88
Price to Book (P/B)39.69
Price to Sales (P/S)31.14
P/FCF Ratio-16.05
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$193.41Price Target Upside2.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Market ApprovalThe FDA approval of Brinsupri for treatment of non-CF bronchiectasis in a broad range of patients supports future growth.
Product LaunchThe launch of Brinsupri (brensocatib) is seen as a key part of Insmed's strategy, offering expansion opportunities into additional neutrophil-mediated indications.
Revenue GrowthInsmed is well positioned for both short term and long term revenue growth, supported by Brinsupri's potential and Arikayce’s continued commercial success.
Bears Say
Effectiveness ConcernsBrensocatib may be less effective in patients with higher eosinophil levels.
Insurance And Pricing ChallengesInsurance pushback and pricing most common reasons limiting uptake.
Market CautionThere is caution against over-interpreting early Brinsupri sales figures, with a clearer understanding expected after the first full quarter of revenue.
Insmed News
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $60.40 and its highest was $194.70 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $40.44B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Feb 19, 2026 which is in 110 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Oct 30, 2025. The company reported -$1.75 earnings per share for the quarter, missing the consensus estimate of -$1.329 by -$0.421.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -1.26.
How many shares outstanding does Insmed have?
Insmed has 211,374,790 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.75 in its last earnings report, missing expectations of -$1.329. Following the earnings report the stock price went up 16.334%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
Insmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$193.41 (2.01% Upside)
$193.41 (2.01% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.29%
12-Months-Change
Fundamentals
Return on Equity
-160.54%
Trailing 12-Months
Asset Growth
37.00%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM Company Deck
INSM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of significant achievements, particularly the strong launch of BRINSUPRI and robust performance of ARIKAYCE. However, the company expressed caution about the early dynamics of the BRINSUPRI launch and uncertainties in market access, indicating a balanced outlook.View all INSM earnings summariesINSM Stock 12 Month Forecast
Average Price Target
$193.41
▲(2.01% Upside)
Technical Analysis
Ownership Overview
0.91% Insiders
31.63% Mutual Funds
0.07% Other Institutional Investors
54.80% Public Companies and Individual Investors